A5050279759- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Viral-associated cancers and disorders
- CAR-T cell therapy research
- Blood groups and transfusion
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Cutaneous lymphoproliferative disorders research
- Sarcoma Diagnosis and Treatment
- CNS Lymphoma Diagnosis and Treatment
- Hemoglobinopathies and Related Disorders
- Gastrointestinal Tumor Research and Treatment
- Hematological disorders and diagnostics
- Platelet Disorders and Treatments
- Autoimmune Bullous Skin Diseases
- Complement system in diseases
- Blood properties and coagulation
- Ocular Diseases and Behçet’s Syndrome
- Ocular Infections and Treatments
- Moyamoya disease diagnosis and treatment
- Lung Cancer Treatments and Mutations
- Blood transfusion and management
- Nutrition, Genetics, and Disease
- Acne and Rosacea Treatments and Effects
- Multiple and Secondary Primary Cancers
- Cancer Genomics and Diagnostics
Gloucestershire Hospitals NHS Foundation Trust
2022-2024
Gloucestershire Royal Hospital
2023
Derriford Hospital
2017-2021
University of Plymouth
2018-2021
University Hospitals Plymouth NHS Trust
2019-2021
Sarah Cannon Research Institute
2020
University College London Hospitals NHS Foundation Trust
2020
University College London
2020
Vall d'Hebron Institute of Oncology
2020
Innsbruck Medical University
2020
Summary Patients with mantle cell lymphoma progressing on Bruton’s tyrosine kinase inhibitor (BTKi) have very poor prognosis and there is currently no standard of care. In this retrospective cohort study, patients BTKi received R‐BAC (rituximab, bendamustine, cytarabine). Overall response rate was 83% (complete 60%) 31% were bridged to allogeneic stem transplant (alloSCT). Median progression‐free survival 10.1 months (95% confidence interval (CI) 6·9–13·3) median overall 12·5 CI 11·0–14·0)....
Summary Ibrutinib is an established treatment for relapsed/refractory (R/R) mantle cell lymphoma (MCL) and clinical trial data supports use at second line compared to later relapse. We aimed investigate outcomes tolerability ibrutinib when given in a real‐world setting. Our multicentre retrospective analysis included 211 R/R MCL patients, median age 73 years, receiving second‐line within the United Kingdom’s National Health Service. Overall response was 69% (complete 27%). The...
Summary Data on older patients with primary central nervous system lymphoma (PCNSL) are scarce. Comorbidities and performance status frequently compromise outcomes in this group. Medical records for consecutive ≥65 years ( n = 244) PCNSL diagnosed 2012–2017 from 14 UK centres were retrospectively reviewed. Of these 192 received methotrexate (MTX)‐based treatment. Patients categorised based clinician's treatment choice into ‘palliative’ 52), ‘less intensive: MTX ± rituximab alkylators’ 74)...
Abstract During the COVID-19 pandemic, ibrutinib with or without rituximab was approved in England for initial treatment of mantle cell lymphoma (MCL) instead immunochemotherapy. Because limited data are available this setting, we conducted an observational cohort study evaluating safety and efficacy. Adults receiving untreated MCL were evaluated toxicity, response, survival, including outcomes high-risk (TP53 mutation/deletion/p53 overexpression, blastoid/pleomorphic, Ki67 ≥ 30%). A total...
Abstract Time to progression of disease (POD) after first-line (1L) therapy is prognostic in mantle cell lymphoma (MCL), although studies have included a broad range 1L, second-line (2L), and subsequent lines therapy. The purpose this study was evaluate the factors predicting outcomes patients with relapsed/refractory (R/R) MCL exclusively initiating 2L Bruton’s tyrosine kinase inhibitors (BTKis) 1L rituximab-containing Patients were accrued from 8 international centers (7 main, 1 validation...
Acute thrombotic thrombocytopenic purpura (TTP) is a life-threatening emergency and plasma exchange (PEX) the initial treatment shown to reduce acute mortality.To compare current practice in United Kingdom (UK) against standards set out 2012 British Society of Haematology guideline, better understand issues affecting prompt initiation PEX.The trainee research network HaemSTAR conducted retrospective nationwide review adults presenting UK hospitals with first episode TTP.Data on 148 patients...
The BSH guideline for the management of mantle cell lymphoma (MCL)1 is under review. Pending full revision document, advent chimeric antigen receptor (CAR) T-cell therapy at third-line has prompted this addendum, focus which to provide additional guidance haematologists on selection, investigation and surveillance MCL patients considered potential candidates future CAR therapy. with who progress or are intolerant a covalent Bruton tyrosine kinase inhibitor (cBTKi) remains significant...
Introduction: Patients with mantle cell lymphoma (MCL) that fail induction treatment represent a difficult-to-treat population poor outcome, where no standard therapy exists. There is paucity of large-scale data in relapsed or refractory (r/r) MCL. Methods: MANTLE-FIRST, an international, retrospective study, evaluated outcomes patients MCL who had progressive disease first relapse when treated upfront high dose cytarabine (HDAC), followed by autologous stem transplantation if appropriate....
In a large multicentre retrospective real‐world analysis, Hess and colleagues describe outcomes in post‐Bruton tyrosine kinase inhibitor (BTKi) mantle cell lymphoma patients managed clinical practice prior to availability of brexucabtagene autoleucel (Tecartus). Outcome data not only provide useful benchmark for future studies but also highlight the great challenges that still lie ahead managing this challenging patient cohort. Commentary on: et al. Real‐world experience among with...
Recent clinical advances in mantle cell lymphoma (MCL) have seen standard-of-care treatment algorithms transformed. Frontline rituximab combination therapy, high dose cytarabine-based induction younger patients and, more recently, Bruton Tyrosine Kinase (BTK) inhibitors the relapse setting all demonstrated survival advantage trials (Wang et al, 2013; Eskelund 2016; Rule 2016). Over last 15 years these practices gradually become embedded practice and real-world data has observed corresponding...